Abstract:Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin protein. Frataxin is involved in the formation of iron-sulfur (Fe-S) cluster prosthetic groups for various metabolic enzymes. To provide a better understanding of the metabolic status of patients with FRDA, here we used patient-derived fibroblast cells as a surrogate tissue for metabolic and lipidomic profiling by liquid chromatography-high resolution mass spectrometry. We found elevated HMG-CoA and β-hydroxybutyrate-CoA levels, implying dysregulated fatty acid oxidation, which was further demonstrated by elevated acyl-carnitine levels. Lipidomic profiling identified dysregulated levels of several lipid classes in FRDA fibroblast cells when compared with non-FRDA fibroblast cells. For example, levels of several ceramides were significantly increased in FRDA fibroblast cells; these results positively correlated with the GAA repeat length and negatively correlated with the frataxin protein levels. Furthermore, stable isotope tracing experiments indicated increased ceramide synthesis, especially for long-chain fatty acid-ceramides, in FRDA fibroblast cells compared with ceramide synthesis in healthy control fibroblast cells. In addition, PUFA-containing triglycerides and phosphatidylglycerols were enriched in FRDA fibroblast cells and negatively correlated with frataxin levels, suggesting lipid remodeling as a result of FXN deficiency. Altogether, we demonstrate patient-derived fibroblast cells exhibited dysregulated metabolic capabilities, and their lipid dysfunction predicted the severity of FRDA, making them a useful surrogate to study the metabolic status in FRDA.

Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia

Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations

Approval of omaveloxolone for Friedreich ataxia

The Regulation of the Disease-Causing Gene FXN

Emerging therapies in Friedreich’s Ataxia

Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs

Emerging antioxidant therapies in Friedreich's ataxia

Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia

A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia

Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia

SS-31 Efficacy in a Mouse Model of Friedreich Ataxia by Upregulation of Frataxin Expression

Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion

Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms

An In Silico Analysis of Genetic Variants and Structural Modeling of the Human Frataxin Protein in Friedreich's Ataxia

Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data

A wearable motion capture suit and machine learning predict disease progression in Friedreich’s ataxia

Iron-Dependent Regulation of Frataxin Expression: Implications for Treatment of Friedreich Ataxia

Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study

Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia

Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich's ataxia

AAV8 Gene Therapy Reverses Cardiac Pathology and Prevents Early Mortality in a Mouse Model of Friedreich's Ataxia